Speaker Bio's: 24th Cancer Center Symposium

Stephen D. Nimer, M.D.

Dr. Stephen D. Nimer is the Director of the National Cancer Institute-designated Sylvester Comprehensive Cancer Center and a Professor of Medicine, Biochemistry and Molecular Biology at the University of Miami Miller School of Medicine. He holds the Oscar de La Renta Endowed chair in Cancer Research. With over 30 years in clinical care, research, and leadership, he has made significant contributions to cancer research and treatment. Prior to joining the University of Miami in 2012, Dr. Nimer spent nearly 20 years at Memorial Sloan-Kettering Cancer Center, where he held multiple leadership roles. Under his leadership, Sylvester became an NCI-designated cancer center in 2019 and reaffirmed its designation in 2024, being the only NCI-designated cancer center in South Florida.
Dr. Nimer is involved with several prominent cancer organizations, including the American Society of Hematology and the American Association for Cancer Research. He has received numerous awards, including "Provost Lifetime Achievement" award and the ASH Mentor of the Year award. Dr. Nimer is an accomplished physician-scientist with over 300 publications and holds patents for leukemia treatments. He has also served on multiple cancer-related foundations and remains continuously funded by the NIH.

Antonio Iavarone, M.D.

As the recently appointed Deputy Director of the Sylvester Comprehensive Cancer Center, Dr. Antonio Iavarone is leading efforts to advance novel

approaches to precision medicine, building on his groundbreaking work in the molecular and systems-level characterization of human brain tumors.

Throughout his career, Dr. Iavarone's research has centered on understanding the biologic and genetic heterogeneity of malignant brain tumors and translating these insights into rational, data-driven therapeutic strategies. His pioneering studies have identified key master regulators of cancer initiation and progression, including the ID proteins in cancer stem cells and the Stat3 and C/EBP transcription factors driving mesenchymal transition in glioblastoma (GBM).

Dr. Iavarone's lab discovered the first oncogenic gene fusion in malignant glioma (FGFR3–TACC3) and demonstrated its role in tumorigenesis through the activation of oxidative phosphorylation. This discovery led to the design of two international multi-institutional clinical trials targeting GBM patients harboring FGFR3–TACC3 fusions (NCT02824133 and NCT02052778) and contributed to the FDA approval of a companion diagnostic assay developed in his lab for the unbiased detection of these variants.

In addition to his translational research, Dr. Iavarone has led several landmark national and international collaborations, including serving as Chair of the ATLAS-TCGA Consortium—which deconvoluted the molecular landscape of sporadic gliomas—and the NF1 Synodos Network, focused on genetically predisposed brain tumors. As the Columbia University Principal Investigator for GBM CARE, an NCI-supported initiative, he advanced single-cell analyses to elucidate mechanisms of GBM resistance and evolution.

Most recently, his team has developed a multi-omics computational framework to define the biological traits of single cancer cells, leading to a new classification of malignant gliomas that integrates clinical stratification with targeted vulnerabilities—laying the foundation for precision oncology initiatives such as the ADAPT-Cancer program.

Suresh S. Ramalingam, M.D., FACP, FASCO

Dr. Suresh Ramalingam is the Executive Director of the Winship Cancer Institute at Emory University and Associate Vice President for Cancer at the Woodruff Health Sciences Center. A renowned thoracic oncologist, he specializes in small cell and non-small cell lung cancer. He holds the Roberto C. Goizueta Chair for Cancer Research and is a Fellow of the American Society of Clinical Oncology.

Aditi Dhir, M.D.

As a pediatric hematologist-oncologist, Dr. Dhir treats children, adolescents and young adults with sarcomas, as well as those with genetic cancer predispositions. Her research focuses on identifying cancer in its earliest stages and utilizing precision medicine to provide better outcomes.

Dr. Aditi Dhir joined Sylvester Comprehensive Cancer Center and the University of Miami Miller School Department of Pediatrics as a clinical assistant professor in the Division of Pediatric Hematology/Oncology in 2020. She earned her medical degree from Lady Hardinge Medical College in New Delhi, India, in 2013. She continued her training with a pediatric residency at Cleveland Clinic Children's Hospital in Ohio, followed by a pediatric hematology and oncology fellowship at Children's of Alabama at the University of Alabama at Birmingham, completed in 2020.

Dr. Dhir is the director of the Pediatric Cancer Predisposition Clinic at the University of Miami which aims to identify children with an inherited risk of cancer to allow for early implementation of surveillance measures. She is also the site principal investigator (PI) for pediatric phase I research studies through the Sunshine Project (National Pediatric Cancer Foundation) and Children's oncology group (COG). In addition, Dr. Dhir is involved in numerous research projects, including therapeutic and non-therapeutic clinical trials for children and young adults with various histologic subtypes of sarcomas and other cancer types.

Dr. Dhir is a peer reviewer for several journals, has published extensively, and has received numerous accolades for her work.

Her funded work includes the V Foundation Early Career Investigator Award (2023-2025) to study the tumor microenvironment and immunological milieu of the patients with sarcoma treated on an autologous dendritic cell vaccine clinical trial as well as the 2022 Micah Batchelor Scholar Awards for Excellence in Children's Health Research, to lead investigations into inhibition of carbonic anhydrase IX to potentiate response to immunotherapy in relapsed/refractory osteosarcoma. By employing strategies involving genetics, epigenetics, and immunotherapy, she hopes to develop translational research that will lead to new treatment paradigms to improve outcomes of children with malignancies and establish herself as an independent clinician-scientist in the field of pediatric oncology.

Adam Resnick, Ph.D.

Trained as a neuroscientist, Dr. Resnick joined the Department of Neurosurgery in 2007 and began developing a laboratory-based research program dedicated to pediatric brain tumors and the context of their developmental biology. Beginning with an early focus on the characterization of the genetic underpinnings of pediatric low-grade gliomas, Dr. Resnick and his research partners engaged efforts to define novel, molecularly informed, targeted approaches for therapeutic intervention in childhood brain cancers.

To support better integration in platforms that would more rapidly inform the preclinical and biochemical modeling of rare diseases, Dr. Resnick and his team launched and participated in new consortia-based approaches for biospecimen-driven research and clinical trials, with the aim of developing scalable ecosystems of collaborative, iterative discovery. These initiatives include the Children's Brain Tumor Tissue Consortium (CBTTC) and the Pacific Pediatric Neuro-Oncology Consortium (PNOC), where Dr. Resnick serves as Scientific Chair. Including more than 20 pediatric hospitals, the consortia

provide for the development of research platforms that fully embrace data-driven approaches for brain tumors across ages, diseases, and institutions.

In 2016, Dr. Resnick launched the Center for Data-Driven Discovery in Biomedicine (D^3b) at CHOP with co-director Dr. Jay Storm, Chief of the Division of Neurosurgery at CHOP. The Center's activities build on the group's experiences in neuro-oncology and focus on collaborative, data-driven science to harness information-systems-based advancements in technology. Comprised of a diverse set of a multidisciplinary team members, D^3b's transformative mission is to build and support a scalable, patient-partnered healthcare discovery and educational ecosystem on behalf of all children.

Jonathan Metts, M.D.

Dr. Metts specializes in the care of adolescents and young adults with sarcoma. He received his MD degree from the University of South Carolina School of Medicine. He completed a Pediatric Residency at the University South Florida Morsani School of Medicine followed by a Pediatric Hematology/Oncology Fellowship at Emory University School of Medicine and the Aflac Cancer and Blood Disorders Center at Children's Healthcare of Atlanta. Dr. Metts joins us from Johns Hopkins All Children’s Hospital in St. Petersburg, Florida where he continues clinical care and research as a part-time Assistant Professor in the Cancer and Blood Disorders Institute. Dr. Metts research interests include novel therapies and clinical trials for patients with sarcomas and other tumors as well as cellular therapy for pediatric solid tumors, including tumor infiltrating lymphocyte therapy. Dr. Metts is Co-Chairman of the National Pediatric Cancer Foundation's Sunshine Project, a clinical trials and translational research consortium comprised of leading pediatric oncology institutions across the United States with a mission to identify more effective and less toxic treatments for children with cancer.

Trey Ideker, Ph.D.

Trey Ideker, PhD, has served as a faculty member at UC San Diego since 2003, with current appointments in the Departments of Medicine, Bioengineering, and

Computer Science and Engineering. Additionally, he holds leadership positions as Director or Co-Director of several federally-funded research centers, including the Cancer Cell Map Initiative, the Bridge2AI Functional Genomics Data Generation Program, and, most recently, an ARPA-H ADAPT Precision Oncology Center.

Ideker received BS and MEng degrees in Computer Science from MIT and a PhD in Genome Sciences from the University of Washington under Drs. Lee Hood and Dick Karp. He was then a David Baltimore Fellow at the Whitehead Institute before joining the UCSD faculty in 2003. He was named a Top 10 Innovator by Technology Review, received the 2009 ICSB Overton Prize, and is a Fellow of the AAAS, AIMBE and ISCB organizations. Ideker previously served as a member of the Board of Scientific Advisors to the NIH National Cancer Institute and National Human Genome Research Institute. He also serves on the editorial boards of *Cell, Cell Systems, PLoS Computational Biology*, and *Molecular Systems Biology*. Since 2020 he has been named a Web of Science Highly Cited Researcher (top 1% by citations). Ideker has published >280 scientific articles to date, which have been cited a total of >119,000 times with a current h-index of 111.

The Ideker laboratory has led seminal studies establishing the theory and practice of systems biology, including systematic techniques for elucidating human cell architecture and its molecular networks. From 2001–present, his laboratory has produced numerous maps of protein-protein, transcriptional, and genetic networks in model organisms and humans (in collaboration with trainees and co-investigators), along with widely used Cytoscape network analysis software (with Gary Bader and others). His studies created methodologies that are now core concepts in bioinformatics, including generation of transcriptional networks to explain genome-wide expression patterns (with Leroy Hood), network alignment and evolutionary comparison (with Richard Karp and Roded Sharan), and network biomarkers, which enable multigenic definitions of patient subtypes and treatment responses. We also introduced experimental mapping techniques, including synthetic-lethal interaction mapping with CRISPR/Cas9 (with Prashant Mali) and characterization of differential interactions across conditions and time (with Nevan Krogan). These technologies have broadly informed the mechanisms by which diverse genetic alterations drive cancer, neurological disorders, and drug resistance. Recently we demonstrated an end-to-end pipeline for mapping the

structure of human cells over a broad scale range, based on fusion of protein networks with immunofluorescence imaging (with Emma Lundberg and Steve Gygi). Ideker has also recently shown that network maps provide a substrate for deep learning models of cell structure and function, with basic implications for the construction of intelligent systems in precision oncology (with Jianzhu Ma and co-investigators). Finally, Ideker and collaborators showed that large parts of the methylome are remodeled with age, leading to the first epigenetic clock and the rapidly expanding field of epigenetic aging.

Seema Verma

Seema Verma is the EVP and GM of Oracle Health and Life Sciences where she is leading the charge to bridge the gap between clinical research and clinical care to improve patient outcomes and care delivery.
She is a national health care expert and recently served as a Senior Advisor to private equity firms TPG and Cressey & Co, serving on the Cressey Distinguished Executive Committee. She also served on the Board of Directors for Lumeris, Monogram, Wellsky, ClaimsXten, Lifestance, and ShiftKey. Additionally, she provided advisory services to a variety of early-stage and large public healthcare companies including national payers and technology companies focusing on strategy, value creation, and operations.
Seema was the former administrator of the Centers for Medicare and Medicaid Services (CMS) between 2017-2021. Confirmed by the Senate on a bi-partisan basis. In this role, she oversaw a $1.4 trillion budget, coverage for 145 million beneficiaries, 6,000+ employees, and over 100,000 contractors. She was responsible for federal operations of Medicare, Medicaid, Health Insurance Exchanges, the Centers for Medicare & Medicaid Innovation (CMMI), and all federal quality and safety regulations.
She developed and implemented the federal administration's healthcare strategic plan across all programs to advance value-based care, innovation, interoperability, and price transparency while reducing drug prices, and regulations through her historic Patients over Paperwork initiative. CMS had numerous accomplishments during her tenure including delivering reduced premiums across Medicare Part D, Medicare Advantage, and individual insurance market as well as addressing the social determinants of health. Her pro-market policies advanced market competition and site-neutral payments.

Her leadership on the White House COVID Task Force led to the widespread adoption of telehealth, Hospital at Home, and no-cost vaccines for the entire country.
Before her role at CMS, she founded and sold a national consulting company and worked as a VP for Policy and Planning for a public hospital, public health department, and health system.
In 2019, Seema was named as Modern Healthcare's Most Influential Person in Healthcare and was part of the Top 25 Women Leaders. She has been published in The Wall Street Journal, Washington Post, Health Affairs, Modern Healthcare, Newsweek, CNN, USA Today, Applied Clinical Trials, Clinical Leader, Clinical Research News, PharmaVoice, STAT, and others.

Sorena Nadaf-Rahrov, MS, MMI

Since co-founding the Cancer Center Informatics Society (Ci4CC) in 2012, Sorena Nadaf-Rahrov has served as its President and Chief Executive Officer, leading the National Cancer Center Initiatives Program (NCIP)—a collaborative framework connecting NCI-Designated Cancer Centers, Biotechnology and Pharmaceutical companies, and Community Oncology programs nationwide. Under his leadership, Ci4CC has become a premier national alliance advancing innovation across clinical & bench to bedside research, artificial intelligence, data science, and biomedical informatics.

A nationally recognized leader in precision oncology, translational research, and clinical trial innovation, Sorena specializes in digital transformation strategies that bridge health systems, research institutions, and life sciences organizations. His work focuses on developing scalable data infrastructures and AI-driven frameworks that enhance patient outcomes and operational efficiency. From 2015 to 2021, Dr. Nadaf-Rahrov served as the Inaugrual Senior Vice President and Chief Informatics/Data Officer at City of Hope, where he founded the Center for Informatics and directed initiatives in clinical and research informatics, data science, and digital health innovation. He co-led the launch of the City of Hope Center for Precision Medicine and architected POSIEDON, an interoperable data ontologies platform still in use today. He was also instrumental in City of Hope’s acquisition of TGen, its enterprise transition to Epic EMR, and the development of integrated systems

for clinical trials, cancer registries, imaging, multi-omics, and research informatics.

Before joining City of Hope, he spent nearly a decade at UCSF as Associate Director and Chief Informatics Officer of the Helen Diller Family Comprehensive Cancer Center, where he founded the Translational Informatics Program, integrated complex data ecosystems, and contributed to the establishment of the Institute for Computational Health Sciences. Earlier in his career, he served over 12 years at Vanderbilt University as the inaugural Chief Informatics Officer and Director of Clinical and Biomedical Informatics for the Vanderbilt-Ingram Comprehensive Cancer Center, supporting the Thoracic Oncology Program under Dr. David Carbone and contributing to early translational research efforts as a bench scientist.

After transitioning from academic health systems in 2021, he served as Interim Chief Data and Informatics Officer at the Alliance for Clinical Trials Cooperative Group and also joined IntegraConnect, where he currently serves as Chief Strategy Advisor for Precision Oncology across Community Oncology Programs.

Sorena remains deeply engaged in NCI-designated Cancer Center External Advisory Boards, national strategy initiatives, and scientific review committees. He serves on the editorial boards of *Experimental Biology and Medicine* and *JCO Clinical Cancer Informatics* and is a former member of the CodeX Steering Committee. He has been recognized as one of the Top 50 Healthcare IT Influencers in 2007, 2015, and 2017.

Stephan Schürer, Ph.D.

Stephan Schürer, PhD is a Professor of Pharmacology at the University of Miami, Associate Director of Data Science at the Sylvester Comprehensive Cancer Center, and Director of Digital Drug Discovery at the Institute for Data Science & Computing (IDSC). His research bridges data science, chemistry, biology, and medicine to drive AI-enabled drug discovery and precision oncology.

Dr. Schürer earned his PhD in chemistry from the Technical University of Berlin and held leadership roles in biotech startups in Silicon Valley before joining Scripps Florida to lead discovery informatics for the NIH Molecular Libraries Program. At Miami, he developed the widely adopted BioAssay Ontology (BAO) and has served as Principal Investigator in multiple national initiatives, including LINCS, IDG, BD2K, RADx, and MorPhiC.
His lab, the Systems Drug Discovery Group, develops scalable data infrastructure and AI tools to support drug repurposing, small-molecule discovery for understudied targets, and precision combination therapies. The team builds full-stack applications and FAIR (Findable, Accessible, Interoperable, Reusable) data platforms that integrate research and clinical datasets to support collaborative, translational biomedical research.

Vasileios Stathias, Ph.D.

Vasileios Stathias, Ph.D., serves as the Assistant Director for Data Science at the Sylvester Comprehensive Cancer Center and the Lead Data Scientist in the Department of Molecular and Cellular Pharmacology at the University of Miami. He oversees the development of the Sylvester Data Portal, a comprehensive multi-omics data platform supporting the FAIR management, automated processing, and intuitive analysis of high-throughput research and Real-World data generated at Sylvester.

Dr. Stathias' research leverages AI and bioinformatics to develop novel precision medicine approaches, and he has led multiple high-impact projects in national cancer research consortia, including NIH LINCS, NCI CPTAC, and AACR GENIE. Dr. Stathias earned his B.Sc. in Molecular Biology and Genetics from the Democritus University of Thrace and completed his Ph.D. in Human Genetics and Genomics at the University of Miami.

Joe Schulin, MSN, RN

Healthcare AI and technology executive with 15+ years of experience bridging clinical insight, data science, and commercial strategy. I help providers, payers, and life sciences organizations unlock the value of precision medicine by turning data into action. Proven track record leading enterprise AI and data-

driven strategies that improve patient outcomes, reduce costs, and accelerate growth. Experienced in scaling new products and partnerships across providers, payers, and government organizations — from ground-up innovation to national commercialization.

Known for “no-box” innovative thinking, team leadership, and a get-it-done mindset that translates bold visions into scalable results. Career foundation as a critical care RN and clinical informaticist, uniquely blending frontline healthcare experience with strategic and commercial expertise. Whether at the bedside, a start-up, or a global enterprise, I thrive on solving complex healthcare challenges and driving transformation through AI, data connectivity, and precision medicine.

Daniel Fabbri, Ph.D., FAMIA

Daniel Fabbri, PhD, FAMIA, is an Associate Professor of Biomedical Informatics and Computer Science. Dr. Fabbri is also the Director of Informatics Innovation at Vanderbilt University Medical Center. He received his PhD in computer science from the University of Michigan before joining the Vanderbilt faculty in 2014.

Dr. Fabbri’s research focuses on data management and machine learning applied to electronic medical records and clinical data. His early research developed privacy and security systems to identify inappropriate use of medical records, which was spun out into the company Maize Analytics, which was acquired in 2021 and again in 2022. During his tenure at Vanderbilt, his research has been sponsored by the National Science Foundation, the National Institutes of Health and the Department of Defense. His recent projects have provided operational support across Vanderbilt University Medical Center through the development of tools for patient engagement, efficient medical record chart review and crowdsourcing services. Beyond research, Dr. Fabbri has taught the Big Data course and mentored undergraduate, master’s and PhD students.

Erin Kobetz, Ph.D.

Dr. Erin Kobetz serves in multiple roles at the University of Miami. As the first Vice President for Health Promotion and Chief Wellbeing Officer, she develops innovative strategies to improve health outcomes and expand access to quality healthcare for individuals across South Florida. As the Associate Director for Community Outreach and Engagement at the Sylvester Comprehensive Cancer Center (Sylvester), she oversees center-wide community outreach and engagement efforts, leading programs that deliver Sylvester's resources to diverse and underserved communities across South Florida, including the Game Changer mobile clinics, which mitigate barriers by directly bringing cancer screenings, health information, and research opportunities to individuals in the catchment areas. Additionally, Dr. Kobetz is the Multiple Principal Investigator (MPI) and Co-Director of the University of Miami Clinical and Translational Science Institute (CTSI). She has co-led CTSI programs focusing on multidisciplinary team science and community and stakeholder engagement since the CTSI's first grant cycle. Dr. Kobetz is a Tenured Professor in the Departments of Medicine, Public Health Sciences, and Obstetrics and Gynecology at UM's Miller School of Medicine and a recipient of the John K. and Judy H. Schulte Senior Endowed Chair in Cancer Research.

She earned a master's in public health from Rollins School of Public Health at Emory University (1999) and joined the University of Miami after completing her Ph.D. at the University of North Carolina at Chapel Hill, Gillings School of Public Health (2004). Soon after, Dr. Kobetz established Patnè en Aksyon (Partners in Action), the University's first-ever community-academic partnership in Little Haiti, the largest enclave of Haitian settlement outside of Haiti, and remains committed to integrating diverse stakeholders into the translational research continuum. As part of her community-based research program, Dr. Kobetz has partnered with firefighters – characterized by excess cancer risk – and leads the Firefighter Cancer Initiative (FCI), a university-wide interdisciplinary program to address this disparity. Such efforts have been locally, regionally, and nationally recognized and serve as an important approach to developing new community-based models for cancer prevention and achieving sustainable health and social change in underserved communities.

Carl Ola Landgren, M.D., Ph.D.

I am Professor of Medicine, Chief of the Myeloma Division and Leader of the Translational and Clinical Oncology (TCO) Program at Sylvester Comprehensive Cancer Center at University of Miami. Over the past several years, I have designed and conducted a series of studies to define biological mechanisms of multiple myeloma and transformation from myeloma precursor disease (monoclonal gammopathy of undetermined significance [MGUS] and smoldering myeloma) to multiple myeloma. In our research laboratory, first at Memorial Sloan Kettering Cancer Center, and now at Sylvester Comprehensive Cancer Center, we have modelled and integrated clinical, immune microenvironment, and genomic data to better characterized the pathogenesis and (sub)clonal evolution of multiple myeloma and its precursor disease, to better evaluate the mutagenic impact of different chemotherapeutic agents, and to improve clinical outcomes.

Our group has strong expertise in both clinical and genome profiling analysis; we have a proven track record on the development of high-throughput laboratory and analytical pipelines (including bioinformatics, statistical modeling, and artificial intelligence); and we have the skills and the experience on how to integrate large and complex genomic datasets. For more than a decade, I have launched several early-interventional clinical trials for patients with high-risk smoldering myeloma, with the aim to delay or prevent transformation. Furthermore, as part of my interest in effective, non-intense therapies, I have designed clinical studies to seek rapid and deep responses in patients with smoldering myeloma as well as newly diagnosed multiple myeloma. Beyond traditional clinical criteria for complete remission, I have developed novel strategies to define minimal residual disease (MRD) detection post-therapy in multiple myeloma and patients with related disorders, using cell-, molecular-, and imaging-based methods. My goal is to define sensitive MRD methods that can be used for longitudinal monitoring without need for invasive biopsies and to use artificial intelligence to integrate these data with genomic, demographic, clinical and therapeutical features to develop individualized prognostication, to redefine the concept of high-risk disease, and

to design, for the first time, patient-tailored therapeutic strategies. In my role, I lead the clinical and research operations as well as the development of the program.

I am a frequent speaker and faculty member for national and international meetings on myeloma and hematologic malignancies. I am on the editorial board for *Haematologica, Leukemia,* and *Blood Advances* and serve as a reviewer for grants and for several high-impact journals. I am a member of American Society of Clinical Investigation (ASCI). I have published over 400 original peer-reviewed publications (pubmed). As a Program Member of the Cancer Center Support Grant, I participate in research activities as an independent investigator, as a leader of research governance committees, and on multi-disciplinary research teams.

Enrique Velazquez-Villarreal, M.D., Ph.D., MPH, MS

As an assistant professor in City of Hope's Department of Integrative Translational Sciences, Enrique Velazquez Villarreal, M.D., Ph.D., M.P.H., M.S., brings more than 14 years' expertise in translational multi-omics research, with a particular emphasis on addressing colorectal cancer health disparities in Hispanic/Latino communities.

A dedicated physician-scientist and computational geneticist, Dr. Velazquez Villarreal received his M.D. in Mexico, then completed a clinical fellowship at Harvard Medical School's Department of Surgery and received a Ph.D., M.P.H. and M.S. at the University of Pittsburgh's Departments of Human Genetics, Epidemiology and Multidisciplinary Public Health and the Pittsburgh Supercomputing Center. Prior to joining City of Hope, he was an assistant professor in the Department of Translational Genomics at the Keck School of Medicine at the University of Southern California (USC).

Dr. Velazquez Villarreal's innovative work includes the development of computational protocols for single-cell multi-omics sequencing and the application of new technologies in spatial transcriptomics within the realm of precision medicine. He has been involved in multiple research programs and projects, including as a founder of USC's Bioinformatics Core and a co-

investigator on the National Institutes of Health-National Cancer Institute Colorectal Cancer Disparities Moonshot project. He was honored with the American Association for Cancer Research's Minority and Minority-Serving Institution Faculty Scholar in Cancer Research Award in 2022.

In his role at City of Hope, he continues to focus on molecularly characterizing colorectal cancer tissues in diverse populations and integrating clinical and multi-omics data to address challenges in the field of precision medicine.

Kelli Rasmussen, MS

Kelli Rasmussen is the associate director of AACR's Project GENIE, where she brings over a decade of expertise in cancer epidemiology, data science, and strategic communication to drive advancements in precision medicine. She is instrumental in managing the day-to-day operations of the Project GENIE Coordinating Center, overseeing collaborative efforts across international institutions, and ensuring the integration of real-world data to enhance clinical decision-making.

Prior to joining the AACR, Kelli served as a senior data scientist at the University of Utah's Division of Epidemiology, where she spearheaded innovative projects like the VetConnect Cancer Navigator within the Veterans Health Administration (VHA). Her work has significantly improved cancer care coordination and the use of advanced computational techniques for oncology research.

Kelli holds a Master of Science degree in sociology with an emphasis on population health sciences from the University of Utah. Her passion for improving patient outcomes through data-driven insights and fostering multidisciplinary collaboration continues to drive her work at the forefront of oncology research and precision medicine.

Jamie Holloway, Ph.D.

Breast cancer survivor with a background in breast cancer research. Experience speaking to scientific, medical, and lay audiences, writing, and providing patient engagement strategies in basic, translational, and clinical research. Excellent communicator with a strength in distilling scientific information to be easily understood by lay audiences.

Helmy Eltoukhy, Ph.D.

Helmy Eltoukhy, Ph.D. is the co-founder and chairman of the board of directors for Guardant Health and has served as the company's Co-Chief Executive Officer since August 2021. Prior to founding Guardant, Dr. Eltoukhy held various positions at Illumina, Inc., or Illumina, from August 2008 to December 2012, including Senior Director of Advanced Technology Research, where he developed novel chemistries, hardware and informatics for genetic analysis systems. In June 2007, he co-founded Avantome Inc. to commercialize semiconductor sequencing to help speed up the democratization of high throughput DNA sequencing and served as Chief Executive Officer until its acquisition by Illumina in August 2008.

He joined the Stanford Genome Technology Center, or SGTC, as a post-doctoral fellow in 2006 to work on low-cost DNA sequencing technologies. During his doctoral studies and at the SGTC, he developed the first semiconductor sequencing platform and first base-calling algorithm for next-generation sequencing under several National Human Genome Research Institute grants. He received his Ph.D., M.S. and B.S. degrees in electrical engineering from Stanford University.

Craig Eagle, M.D.,

Craig Eagle is an accomplished Chief Medical Officer at Guardant Health, specializing in the pharmaceutical preparations industry. With extensive experience in biotechnology and clinical development, he has held leadership

roles at prestigious organizations like Genentech and Pfizer. His expertise spans various therapeutic areas, including cardiology, oncology, and infectious diseases, showcasing his versatility in the medical field.

Craig has a proven track record in drug development and regulatory affairs, making him a key player in advancing healthcare solutions. His leadership style emphasizes cross-functional collaboration and strategic planning, essential for navigating complex clinical trials. Based in San Francisco, he is at the forefront of medical innovation, contributing to the evolving landscape of life sciences. Craig's commitment to improving patient outcomes drives his work in clinical research and medical affairs. He is recognized for his ability to lead diverse teams in high-stakes environments, pushing the boundaries of what's possible in medicine.

Jason Porter, M.D.

I work Guardant Health as Vice President of Clinical Education, and I am a practicing medical oncologist serving the greater Memphis Metropolitan Area! I spend my clinical time caring for patients with lung cancer. My research time is dedicated to clinical research and trials focused on advancing the therapeutic armamentarium used to treat and cure thoracic malignancies. I’m the father of one beautiful daughter and two curious little Maltese brothers. When not working, I enjoy listening to music across all genres and eating lots of good food! Then, I spend time complaining about losing the weight gained and enjoy light weight-training and cardio. I’m open to philosophical and scientific discussion around health and lung cancer.

Steve Rosen, M.D., FACP, FASCO, FAIMBE

Steven T. Rosen, M.D., is a professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, and executive vice president and director emeritus, Comprehensive Cancer Center and Beckman Research Institute of City of Hope®.

Prior to joining City of Hope, Dr. Rosen was the Genevieve Teuton Professor of Medicine at the Feinberg School of Medicine at Northwestern University in

Chicago. He served for 24 years as director of Northwestern's Robert H. Lurie Comprehensive Cancer Center. Under his leadership, the center received continuous National Cancer Institute (NCI) funding beginning in 1993 and built nationally recognized programs in laboratory sciences, clinical investigations, translational research and cancer prevention and control. The center attained comprehensive status in 1997.

Dr. Rosen has published more than 400 original reports, editorials, books and book chapters. His research has been funded by the NCI, American Cancer Society, The Leukemia & Lymphoma Society and Multiple Myeloma Research Foundation. Dr. Rosen also has served as an adviser for several of these organizations and on the external advisory boards of more than a dozen NCI-designated comprehensive cancer centers. He is the current editor-in-chief of the textbook series "Cancer Treatment & Research."

Recognized as one of the "Best Doctors in America," Dr. Rosen is a recipient of the Martin Luther King Humanitarian Award from Northwestern Memorial Hospital and the Man of Distinction Award from the Israel Cancer Research Fund. He is also a member of the American Institute for Medical and Biological Engineering’s College of Fellows. Dr. Rosen earned his bachelor's degree and medical degree with distinction from Northwestern University and is a member of the Alpha Omega Alpha Honor Society.

Reena Duseja, M.D., MS

Chief Medical Officer for Quality Measurement and Value-Based Incentives Group, Centers for Clinical Standards and Quality Centers for Medicare and Medicaid Services

Dr. Duseja is an emergency medicine physician and prior to coming to CMS, was an Associate Professor at the University of California, where she led quality improvement activities in a large county hospital and was awarded funding by NIH to conduct studies related to improving patient care and value for the health system. As a Robert Wood Johnson Clinical Scholar at the University of Pennsylvania, her research focused on quality of care and unintended consequences of measurement. She received her MS in Health

Economics at Wharton, Heath Care Management and Economics, at the University of Pennsylvania.

Alexy Aleshin, M.D, MBA

Alexey Aleshin serves as general manager of oncology and early cancer detection & chief medical officer of Natera. He joined the company in 2017, and has served in many leadership capacities during his tenure including medical director of oncology, vice president of oncology medical affairs, and chief medical officer.

Aleshin has a demonstrated history of working in the biotechnology industry, with a focus on circulating biomarkers and novel clinical trial design and execution. He is an experienced product strategist and cross functional team manager. Earlier in his career, he served as an advisor and consultant for various companies focused on advancing clinical adoption of next generation sequencing technologies.

Aleshin holds his M.D. and an MBA from UCLA. He completed his internal medicine residency at Stanford University Medical Center and his hematology/oncology fellowship at Stanford Hospital.

Sanjay Juneja, M.D.

Dr. Sanjay Juneja, a hematologist and medical oncologist widely recognized as “TheOncDoc,” is a trailblazer in healthcare innovation and a rising authority on the transformative role of AI in medicine. Garnering over 750k followers and 50 million views on social media, Dr. Juneja’s unique ability to simplify complex topics has earned him global acclaim. His debut podcast, Target Cancer: Podcast, amassed 4+ million downloads in over 120 countries within just two years, setting the stage for his current AI-focused series featuring world-renowned guests.

Dr. Juneja's accolades include being named Targeted Oncology's inaugural 2024 Oncology Icon, an invitation to the White House's 2023 Healthcare Leaders in Social Media Roundtable, and recognition as a 40 Under 40 honoree and one of the Capital Region's Top 500 Most Influential Leaders for three consecutive years. His insights have been featured in The Washington Post, WIRED, Bloomberg, and PBS.

In addition to founding TensorBlack, an educational platform specializing in AI applications in oncology, Dr. Juneja serves as Vice President of Clinical AI Operations at Tempus AI and a contributing writer + Technology council for *Forbes*. He is credentialed by Harvard Medical School's inaugural AI in Healthcare: *From Strategies to Implementation* Executive Education, and an Editorial Board Member for the peer-reviewed journal *AI in Precision Oncology*.

Frank Penedo, PhD

Dr. Frank J. Penedo is a professor in the Departments of Psychology and Medicine, Associate Director for Population Sciences at the University of Miami Sylvester Comprehensive Cancer Center, and the Sylvester DCC Living Proof Endowed Chair in Cancer Survivorship. He earned his PhD in clinical health psychology from the University of Miami. He completed his clinical residency in psychosocial oncology and behavioral medicine at the University of Pittsburgh Medical School. His work investigates the biopsychosocial mechanisms underlying chronic disease and assesses the effectiveness of evidence-based psychosocial interventions—either in person or via technology—in managing cancer and improving both patient-reported and clinical outcomes. Dr. Penedo also conducts translational dissemination and implementation research focused on addressing unmet survivorship care needs, as well as monitoring and managing symptoms and toxicities in ambulatory oncology, leveraging advances in electronic health records (EHR) and AI technologies. He is an internationally recognized leader in cancer survivorship, psychosocial and behavioral interventions, patient-reported outcomes, and digital health. As Director of Cancer Survivorship and Supportive Care at Sylvester, he oversees implementing supportive care standards and aligning them with translational research programs that evaluate the effects of distress screening, symptom and toxicity monitoring,

and survivorship care delivery at Sylvester. He has served as President of the International Society of Behavioral Medicine, and his research and mentoring have been honored with numerous awards from prestigious organizations in his field. He is an elected fellow of the Society of Behavioral Medicine, the Academy of Behavioral Medicine Research, and the International Society of Behavioral Medicine. He has also participated in numerous NIH study sections and served as a senior associate editor and reviewer for multiple journals. Dr. Penedo has authored over 350 peer-reviewed publications on cancer survivorship and disease management, has been continuously funded by the NIH for the past 23 years, and is a member of the NIMHD Council.

Jerry Bonnel PhD

Post Doctoral Associate, Institute for Data Science and Computing, Schools & Colleges, University of Miami

---

Molly Bryant

Molly Bryant is a seasoned digital marketing executive and product evangelist with a strong focus on B2B SaaS. With extensive experience across various company sizes, from startups to Fortune 500 firms, she excels at aligning go-to-market strategies with customer needs. Molly is known for her empathetic leadership style and data-driven approach, particularly in the customer buying journey. Her expertise spans marketing strategy, technology operations, and sales enablement, making her a key player in driving business growth. She has successfully launched multiple products and has a proven track record in demand generation and digital marketing. Molly's passion for storytelling enhances her marketing initiatives, connecting deeply with audiences. She holds a Bachelor of Science in International Affairs from Georgia Institute of Technology, which complements her marketing acumen with a global perspective.

Akina Natori, M.D.

Dr. Akina Natori earned her medical degree from Nagoya University and completed her residency and oncology fellowship at St. Luke's International Hospital in Japan, followed by a clinical and research fellowship at Princess Margaret Cancer Centre in Toronto, Canada. She is a cancer survivorship researcher whose work aims to improve long-term health outcomes and quality of life among individuals recovering from cancer. Her research integrates patient-reported outcomes, clinical and demographic data, and advanced analytic methods to identify factors that influence survivorship and to inform personalized, data-driven care strategies.

A central focus of Dr. Natori's work involves leveraging patient-reported outcomes to better understand the symptom burden, functional recovery, and psychosocial well-being of cancer survivors. She uses large, real-world datasets to examine how changes in patient-reported outcomes over time can predict clinical outcomes and guide timely interventions. By combining patient-centered data with clinical information, her research provides critical insights into the lived experiences of survivors and highlights opportunities to enhance survivorship care delivery.

Mitsunori Ogihara Ph.D

Dr. Mitsunori Ogihara joined the University of Miami in 2007 as Professor in the Department of Computer Science and as Program Director of the Big Data Analytics & Data Mining Program for the Center for Computational Science (now IDSC). More recently, he served as Associate Dean for Digital Library Innovation in the College of Arts and Sciences. He is currently the Director of IDSC Workforce Development and Education, and Site Director for NSF University of Miami CARTA. Dr. Ogihara holds secondary appointments in the Department of Electrical and Computer Engineering in the College of Engineering and the Department of Music Media and Industry in the Frost School of Music.

Dr. Ogihara obtained his PhD in Information Sciences from the Tokyo Institute of Technology in 1993. From 1994 to 2007, Dr. Ogihara was a Computer Science faculty member at the University of Rochester, where he was promoted to Associate Professor with tenure in 1998, and to Full Professor in 2002. He also served as Chair of the Department from 1999 to 2007.
His research interests are in data mining, information retrieval, network traffic data analysis, program behavior analysis, molecular computation, and music information retrieval. A prolific scholar, Dr. Ogihara has authored/co-authored three books The Complexity Theory Companion, Music Data Mining, and Fundamentals of Java Programming, and the author of more than 200 peer-reviewed research papers. Many papers by Dr. Ogihara are through interdisciplinary collaborations. His articles appear in journals and conferences that cover many fields, including psychology, implementation science, library science, chemistry, biology, and digital humanities. He is currently serving as Editor-in-Chief for the Theory of Computing Systems Journal (Springer) and on the editorial board for the International Journal of Foundations of Computer Science (World Scientific).

Ravi Vadapalli, Ph.D

Dr. Vadapalli joined IDSC after serving as Program Director for the Center for Agile and Adaptive Additive Manufacturing and Senior Director for IT Support at the University of North Texas (UNT) in Denton. Prior to UNT, Dr. Vadapalli was a Senior Research Scientist at the High-Performance Computing Center at Texas Tech University (TTU) in Lubbock. In those roles, he helped secure nearly $3 million dollars in external funding, more than $40 million in grant proposals, and more than $230 million in-kind grants for skilled workforce training.

One of Dr. Vadapalli's priorities is advancing cancer care and research through machine learning (ML), artificial intelligence (AI), and powerful computer models. At TTU, he partnered with researchers at M.D. Anderson Cancer Center and Rice University to accelerate the development of patient treatment plans.

Dr. Vadapalli is also interested in applying advanced computing tools to

develop sophisticated climate models involving ocean and atmospheric conditions. Dr. Vadapalli holds a Doctorate in Nuclear Physics from Andhra University in India, and a Master's degree in Computational Engineering from Mississippi State. He and his wife have two sons.

Jonathan C. Trent, MD, PhD
Professor of Medicine, Associate Director for Clinical Research.
Director, Sarcoma Medical Research Program.
Director, Precision Medicine Program.
Sylvester Comprehensive Cancer Center
University of Miami, Miller School of Medicine

Dr. Trent focuses his clinical, educational, and research efforts on GIST, chondrosarcoma, and other sarcomas. His interests include the clinical and translational research of sarcomas, the direct care of patients with sarcoma, and education about sarcoma and patient-oriented research. As Associate Director for Clinical Research, his goal is to help Sylvester faculty develop clinical trials that provide clinically effective and scientifically exciting therapy to patients with cancer. The major efforts of Dr Trent's research focus on understanding the mechanisms of action and resistance of imatinib in GIST and other sarcomas while striving toward improved therapeutic options. His work involves the use of novel preoperative/postoperative clinical trials, prospectively acquired tumor tissue, cell lines, and archival tissue.

Amrit Paudel, M.D.
Amrit Paudel is a Hematology/Oncology Fellow at the University of Miami/Jackson Health System, with special interest in sarcoma, lung cancer, and disparities in health care. Originally from Nepal, he completed his residency in internal medicine at MedStar Health in Maryland/DC under Georgetown University. His clinical and research interests focus on targeted therapies for sarcoma and lung cancer, as well as addressing healthcare disparities to improve access to cancer care in underserved populations.

Nicholas Borja, M.D.

Dr. Borja is a board-certified clinical geneticist born and raised in Miami who strives to provide excellent care to his patients in the South Florida community. His expertise lies in diagnosing and managing rare genetic disorders in both pediatric and adult patients. Dr. Borja also conducts research at the University of Miami in the field of hereditary cancer susceptibility and as an investigator for the Undiagnosed Diseases Network. He places a special emphasis on enhancing patient outcomes through individualized care.

Emily Jonczak, M.D.

Dr. Emily Jonczak received her medical degree from St. George's University School of Medicine, completed her residency in Internal Medicine at Cleveland Clinic – Florida, and her fellowship in Hematology/Oncology at the University of Miami/Jackson Memorial Hospital. She has a clinical interest in sarcoma and connective tissue disorders, and is board certified in both Medical Oncology and Internal Medicine.

Tracy Crane, Ph.D

Dr. Tracy E. Crane is an internationally recognized thought leader in cancer prevention and control, specializing in digital health interventions to improve patient outcomes. She is an Associate Professor of Medical Oncology, Public Health, and Kinesiology at the University of Miami and Co-Leader of the Cancer Control Research Program at Sylvester Comprehensive Cancer Center. As Director of Lifestyle Medicine, Prevention, and Digital Health, she leads a multidisciplinary research team focused on innovative lifestyle interventions, leveraging AI-driven technology to deliver precision behavioral strategies. In the last 5 years, she has secured over $30 million in research funding, including multiple National Cancer Institute (NCI)-funded studies and a large PCORI-funded trial, and has authored over 100 peer-reviewed publications, including co-authoring the latest American Cancer Society

guidelines on nutrition and physical activity for cancer survivors. A registered dietitian with a Ph.D. in Nursing Science, Dr. Crane also serves as Chair for Cancer Prevention and Control nationally for NRG Oncology's NCI Community Oncology Research Program. Her pioneering contributions have made her a sought-after speaker and leader in the global effort to integrate digital health and personalized lifestyle medicine into cancer prevention and care.

Harleen Kaur, Ph.D

Dr. Harleen Kaur is a Post-Doctoral Research Fellow at the Sylvester Comprehensive Cancer Center. Her dissertation training encompassed the implementation of both digital and community-based diet and physical activity interventions tailored for cancer survivors.

The focus of her dissertation was to elucidate the operative mediators of web-based interventions for cancer survivors, and to advance the understanding and efficacy of lifestyle interventions to enhance dietary and physical activity behaviors. As a researcher, her ultimate aspiration is to improve the quality of life for cancer survivors through the provision of personalized diet and physical activity interventions across the cancer continuum.

Marvin Rothwell, Ph.D

I am currently the Assistant Director, Research Systems and Infrastructure at Duke Cancer Institute, where I lead a team focused on managing research technology solutions from conception to end of life. I also lead the Cancer Registry team that manages all data for cancer incidence, occurrence, and survivorship. My experience covers over 20 years in data and analytics, process improvement, and consulting across various industries, including health care, manufacturing, and supply chain optimization. I hold a PhD in Industrial and Systems Engineering and several certifications in IT service management and Six Sigma.

My mission is to leverage my data driven decision making, process engineering

mindset, and strategic vision to deliver innovative and impactful solutions that enhance the performance and outcomes of my teams. I have redesigned the IT structure, implemented an internal work tracking system, and integrated the Cancer Registry team into Duke Cancer Institute Informatics. I am passionate about collaborating with diverse resources and cross-functional teams, building long-lasting relationships with stakeholders and partners, and driving tactical innovations that meet client needs and exceed expectations.

Alexy Aleshin, M.D., Ph.D

Alexey Aleshin serves as general manager of oncology and early cancer detection & chief medical officer of Natera. He joined the company in 2017, and has served in many leadership capacities during his tenure including medical director of oncology, vice president of oncology medical affairs, and chief medical officer.

Aleshin has a demonstrated history of working in the biotechnology industry, with a focus on circulating biomarkers and novel clinical trial design and execution. He is an experienced product strategist and cross functional team manager. Earlier in his career, he served as an advisor and consultant for various companies focused on advancing clinical adoption of next generation sequencing technologies.

Aleshin holds his M.D. and an MBA from UCLA. He completed his internal medicine residency at Stanford University Medical Center and his hematology/oncology fellowship at Stanford Hospital.

Solomon Moshkevich, MBA

Solomon Moshkevich serves as president of clinical diagnostics at Natera, where he oversees productization, clinical validation, commercialization, and quality across the company.
Since joining Natera in 2011, Moshkevich has built and led multiple teams including global marketing, product management, medical and scientific

affairs, commercial operations, clinical trial operations, business development, international sales, program management, and portfolio strategy. He has played a leading role in the development, clinical validation, and commercial success of all of Natera's cell-free DNA products including Panorama, Prospera, and Signatera.

David Lombard, M.D., Ph.D.

Dr. David Lombard received his MD from Harvard Medical School, and his PhD at MIT, where he studied Werner syndrome and related premature aging diseases. After Anatomic Pathology residency at the Brigham and Women's Hospital in Boston, Dr. Lombard pursued postdoctoral work in the area of the biology of sirtuins – cellular enzymes involved in metabolism, cancer, and aging – supported by an NIH K08 award. Dr. Lombard was the first to describe a central role for the sirtuin SIRT3 in regulating the mitochondria, the powerhouses of the cell. He set up his first independent lab at the University of Michigan in 2008, where he rose to the rank of tenured Associate Professor, and directed the NCI T32-supported Cancer Biology Ph.D. program. He was named an elected member of The American Society for Clinical Investigation, a New Scholar in Aging of the Ellison Medical Foundation, a Scholar-Innovator of the Harrington Discovery Institute, and a recipient of an AACR Innovation and Discovery award. He serves a member of many NIH, DoD, and foundation grant review panels.

Dr. Lombard joined the faculty of the Miller School of Medicine in the spring of 2022, where he is a Professor and Vice-Chair for Clinical and Translational Research in the Department of Pathology & Laboratory Medicine. He is also a Physician and Staff Scientist at the Miami Bruce W. Carter VA Medical Center. At the Sylvester Comprehensive Cancer Center, Dr. Lombard serves as Site Disease Group Physician Co-Leader and Translational Science Leader of the Sarcoma Oncology Service Line and co-leads the Cancer Epigenetics program. His lab focuses on elucidating interrelationships between aging, metabolism, and cancer.

Kojo S.J. Elenitoba-Johnson, M.D.

Kojo S. Elenitoba-Johnson is the Chair of the Department of Pathology and Laboratory Medicine and a physician-scientist. Dr. Elenitoba-Johnson's research focuses on the role of genomic and proteomic alterations in the pathogenesis of lymphomas.

Dr. Megan S. Lim is the Director of the Lymphoma Translational Research Program and Director of the Biofluid Biobank. Dr. Lim is a hematopathologist-scientist who studies the role of genomic and proteomic alterations in the pathogenesis of lymphoma.

The research interests of the Elenitoba-Johnson-Lim lab encompass genomic and functional proteomic approaches to discover novel mechanisms of lymphoma pathogenesis; development of conditional murine models for investigating the role of oncogenes and tumor suppressor genes in lymphocyte development and lymphomas genesis and translational research utilizing innovative genomic and mass spectrometry-based approaches focused on identification of novel genomic and proteomic targets for diagnostic and therapeutic applications.

Katie Thoren, Ph.D.

Katie Thoren, P.h.D., is clinical chemist who specializes in translating new technologies into the clinical laboratory. Dr. Thoren focuses on improving the measurement of proteins and antibodies through use of techniques such as mass spectrometry, surface plasmon resonance and microfluidic immunoassays. In particular, she is using novel mass spectrometry approaches for the detection of monoclonal immunoglobulins in serum and urine.

Although these techniques have been traditionally limited to research settings, they offer improved sensitivity and specificity over current clinical diagnostic methods. Dr. Thoren's work focuses on understanding how to best translate

these techniques into routine use. Through collaborations with clinicians and in vitro diagnostic manufacturers, her translational research aims to keep the clinical laboratory at the forefront of diagnostic testing so we can provide the best possible care for our patients. Dr. Thoren's training in protein biochemistry, mass spectrometry and clinical chemistry make me well suited for this role.

Eric Durbin, DrPH, MS

Dr. Durbin is an associate professor and serves as the director of the Kentucky Cancer Registry. He is a principal investigator of the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) and the Centers for Disease Control and Prevention's National Program of Cancer Registries (NPCR) programs in Kentucky. He also serves as director of the Cancer Research Informatics Shared Resource at the Markey Cancer Center and as co-director of the Biomedical Informatics Core of the UK Center for Clinical and Translational Science (CCTS). He serves on two state boards focused on pediatric cancer research and colorectal cancer screening.

Dr. Durbin has over three decades of experience in population-based cancer surveillance and biomedical informatics support for basic, clinical, population, and translational cancer research. As an advocate for biomedical data standardization, integration, and use, he has established one of the most mature and comprehensive cancer surveillance infrastructures in the United States.

Kentucky leads the nation in population-based electronic pathology reporting and is the first state cancer registry to routinely collect clinical molecular test results. Dr. Durbin leads UK's efforts to expand participation in the National Institutes of Health (NIH) sponsored National Clinical Cohort Collaborative (N3C) to include data for cancer and kidney disease and is also leading UK's participation in the NIH Data Collect Once Use Numerous Times (COUNTS) initiative.

To facilitate research into the high burden of childhood cancer in Kentucky and Appalachia, he established the Appalachian and Inner City Pediatric,

Adolescent, and Young Adult Cancer Data Ecosystem (ACCELERATE) Consortium, a unique data sharing initiative that brings together leading cancer centers treating patients in the Appalachian region. As an internationally recognized leader in population cancer surveillance, he was elected to serve as president of the North American Association of Central Cancer Registries, beginning in July of this year.

Dr. Durbin's current research focuses on the integration of multi–omics data to support strategic planning and decision-making in precision medicine and in cancer prevention and control. His research team develops informatics methods to support population-based cancer research and machine learning methods to derive biomarkers and features from narrative clinical documents and pathology digital whole slide images.

He also leads epidemiological studies exploring environmental, genetic, and other risk factors associated with the high incidence of childhood brain and central nervous system tumors in Kentucky and the Appalachian region.

Dr. Durbin earned degrees in biology and computer science from Transylvania University and UK and his doctorate in epidemiology from the UK College of Public Health.

George S. Grills

I have experience in research and in research administration, including oversight of research projects, technologies, finances and human resources. I have played leadership roles in establishing and supervising individual research core facilities, cancer center shared resources, genome centers, clinical diagnostic laboratories, and large-scale institutional core facility centers.

My expertise includes ensuring that a broad range of biotechnologies are efficiently operated and effectively catalyze research. I also have experience in the evaluation, development, acquisition, and application of new technologies. I have initiated and coordinated large-scale research projects; written manuscripts and successful grant proposals; participated on

executive boards, advisory boards and grant review panels; and organized local, regional and international conferences. To support key initiatives, I have developed close working relationships with institutional leadership, investigators, key staff across large organizations, advisory committees, consultants, funding agencies, academic institutions and commercial enterprises. I have experience in developing, communicating, and implementing strategic visions and initiatives. Moreover, I have a broad understanding and a keen interest in both basic and translational research.

Alvaro Monteiro, Ph.D.

As the Associate Center Director of Shared Resources Management, Dr. Alvaro N.A. Monteiro oversees the portfolio of current and developmental Shared Resource (Core) laboratories/facilities to support exceptional science by Moffitt faculty members. In this role, he provides strategic vision, direction and monitoring of activities.

Dr. Monteiro's academic training includes a bachelor's degree in Genetics and a PhD in Biochemistry and Molecular Biology from the Federal University of Rio de Janeiro. He did postdoctoral work in molecular oncology at the Rockefeller University. Before moving to Moffitt in 2003, he was an Assistant Professor at the Weill Medical College of Cornell University in New York City.

He is a Moffitt Distinguished Scholar and a Senior Member in the Population Sciences Division at Moffitt and a Professor in the Department of Oncologic Sciences at the University of South Florida. Dr. Monteiro is a member of the National Cancer Institute Board of Scientific Counselors. He is a member of the American Association of Cancer Research and participates in the training of molecular epidemiologists specializing in cancer since 2014 as a faculty member in the AACR Workshop on Integrative Molecular Epidemiology.

His research aims to understand how rare and common genetic variation impacts cancer risk and rewires signal transduction networks. His laboratory pioneered functional assays for the major breast cancer susceptibility gene *BRCA1* and contributed to the development of tools for clinical

annotation of rare variants in *BRCA1*, *BRCA2*, *PALB2* and *CHEK2* in hereditary breast and ovarian cancer syndrome.

Stephan Schurer, Ph.D.

Dr. Schürer studied chemistry at Humboldt University of Berlin and University of California Berkeley. Following his PhD from the Technical University Berlin, he built and directed the international operations to the develop life science information technology and scientific content products at Libraria and Eidogen-Sertanty Inc, two technology startups in San Jose California where he was a founding member. After building the operational and discovery cheminformatics platform at Scripps Florida to support Scripps Drug Discovery and the Scripps Molecular Libraries Screening and Probe Discovery Program, he started his academic career at the University of Miami.

At Miami he developed the BioAssay Ontology (BAO) which has become the de-facto standard to describe drug discovery assays and is widely used across the industry. Among numerous research collaborations, Dr. Schürer has served as Principal Investigator in several national and international research consortia, the Molecular Libraries Program (MLP), Library of Integrated Network-based Cellular Signatures (LINCS), Big Data to Knowledge (BD2K), Illuminating the Druggable Genome (IDG), Rapid Acceleration of Diagnostics (RADx), and Molecular Phenotypes of Null Alleles in Cells (MorPhiC).

Richie Reich, Ph.D.

Moffitt Cancer Center is a top 10 Cancer Center in the United States. I am an experienced research methodologist having held various research positions since 1995, including lab technician, graduate assistant, post doc, biostatistician, tenured faculty member, Faculty Coordinator of Research, and currently Manager of the Biostatistics and Bioinformatics Shared Resource at Moffitt. Tangible strengths include quantitative analysis, teaching, and writing. Intangible strengths include ambition, leadership, and integrity.

Yi Gua, Ph.D., FAMIA

Dr. Guo is Associate Professor, Associate Chair for Data Science, and Division Chief (Preeminent Scholar) of Biomedical Informatics and Data Science in the Department of Health Outcomes and Biomedical Informatics at the University of Florida. He also serves as the Chief Data Scientist and Director of the Cancer Informatics Shared Resource for the UF Health Cancer Institute, Co-Director of the UF CTSI Biomedical Informatics Program, as well as the Associate Director of the Office of Data Science Research for the OneFlorida+ Clinical Research Network.

Dr. Guo has a multi-disciplinary background in the analysis of real-world data such as those from electronic health records (EHRs) and administrative claims, randomized trial and observational study design, predictive modeling (e.g., statistical and machine learning), causal modeling, and the analysis of patient-reported outcomes (PROs).

Together, Dr. Guo's areas of expertise serve an overarching research theme: generating real-world evidence to support healthcare decision-making for disease prevention and control. Under this overarching theme, Dr. Guo's research areas and expertise can be divided into three key methodologies: (1) EHR-based phenotyping and risk stratification – the identification of sub-populations with certain conditions or at higher risk for diseases, (2) Causal modeling and inference – the examination of causal relationships and pathways in clinical research, particularly treatment studies, and (3) PROs in clinical and public health applications – the development, validation, assessment, analysis, and reporting of PROs among various populations, especially vulnerable populations.

Sophia George, Ph.D.

Dr. Sophia George, PhD is a Professor in the Division of Gynecological Oncology within the Department of Obstetrics and Gynecology at the Leonard M. Miller School of Medicine. She is a molecular geneticist graduate from the

University of Toronto, then did her post-doctoral training in molecular pathology in Gynecological Pathology at Princess Margaret Cancer Center within the Ontario Cancer Institute and a second post-doc at Duke University in the Department of Medical Oncology in Hereditary breast cancer syndrome.

A native of the Caribbean, she leads a team of multi-disciplinary team who studies the incidence of Hereditary Breast and Ovarian Cancer syndrome genetic mutations in Africa and the African diaspora. Her research interests lie in studying pathogenesis of sporadic and hereditary breast and ovarian cancers and uses multi-omics approaches to study disease pathogenesis, variation across populations and overall outcomes of women diagnosed with these diseases. She is the President and co-Principal Investigator and founder of the Transatlantic Gynecologic Cancer Research Consortium and facilitated the establishment of 2 Gyn Oncology fellowship programs in the Bahamas and Nigeria with the University of Miami and the International Gynecologic Cancer Society

---

Jasmine Plummer, Ph.D.

At St. Jude Children's Research Hospital, my role as Director and Associate Member centers around pioneering genomic research strategies computational tools to combat disease. Leading a team that integrates large-scale multi omic data, we have been instrumental in advancing the understanding how disease arises.

With a robust foundation in molecular genetics, neuroscience and cancer, my approach to research is deeply rooted in innovation and thoroughness. Our lab's current focus on using spatial technologies and AI/ ML tools demonstrates our commitment to unraveling the mysteries of genetic influence in cancer susceptibility and pathogenesis.

Sara Linker, Ph.D.

Computational biologist skilled in bioinformatics including transcriptomics, genomics, machine learning, high-dimensional data processing and creatively adapting these methodologies within the context of biology.

Reena Duseja, M.D., M.S.

Dr. Reena Duseja is a Physician Executive and Senior Director at Oracle Health and Life Sciences. As a board-certified Emergency Physician, she has 25+ years of experience at the intersection of academia, federal policy and health IT to drive systems-level change.

Christine Swisher, Ph.D.

I enjoy tackling the hard problems and doing them well, building AI and data solutions that embody the ethos of “Do no harm - and the most good”. Notably, the AI solutions my team has built saved lives that would otherwise have been lost, while also enhancing health economics and the clinical experience and accelerating discovery.

My expertise includes growing productive and thriving teams with a people-first approach, empowering patients and clinicians via data insights, driving the full AI life cycle from idea to meaningful impact, igniting innovation in organizations, and being a strategic and systems thinker focused on meaningful impact at scale.

Let's collaborate to create a better world.

Chris Lewis, M.D., FACHE

Dr. Lewis partners with clinical and executive leaders by leveraging his expertise in change management and governance to guide health care organizations on a lifelong journey of continuous process improvement complemented by innovative information technology. He directly impacts clinicians and their patients by carefully listening to practice challenges followed by broad collaboration to facilitate efficient process solutions. Chris joined Oracle Health (Cerner) in 2010 as a consulting physician executive.

A combination of clinical process acumen, effective communication style, and trustworthiness contributes to his success as a clinical informatics leader. Focused on continuing professional development to enhance clinical care quality and safety, he is privileged to have served fellow clinicians as a manager and mentor. He is a 1994 graduate from the University of Kansas School of Medicine. Sponsored by the United States Air Force, he completed medical specialty training for internal medicine and medical oncology with subsequent practice in both military and civilian venues of care.

Finley Zachariah, M.D.

Finly Zachariah, M.D., is recognized as a compassionate and highly skilled supportive medicine physician, providing symptom management, pain control and palliative care for adult and pediatric patients.

He is board certified in Family Medicine, Hospice & Palliative Medicine, and Clinical Informatics. After earning his medical degree from Chicago Medical School, he completed a Family Medicine/Tropical Medicine residency in Whittier at Presbyterian Intercommunity Hospital, followed by a fellowship in Hospice and Palliative Medicine at Kaiser in Los Angeles. Combining his training in tropical medicine with his humanitarian values, Dr. Zachariah has volunteered significant time in underserved parts of the world teaching palliative care and helping patients in Cameroon, Zambia, India and Ethiopia.

He also serves as an associate chief medical information officer, supporting his colleagues in the adoption of clinical technologies and refining the electronic health record system to improve care delivery. His programmatic and academic focus includes tailoring patient care to individual values and goals, advance care planning, and leveraging technology to enhance the coordination and delivery of patient-centered medical care in serious illness. Dr. Zachariah is available by referral to help patients address issues of pain or other supportive care needs.

Julia Sanchez, M.D., MBA

I am a seasoned healthcare professional with a diverse background in pain medicine, palliative care, and internal medicine. My educational journey includes obtaining a Healthcare Executive MBA from the University of Miami, complementing my medical degree, residency at Yale University Program at Bridgeport Hospital and fellowship at Memorial Sloan Kettering Cancer Center. With active medical licenses in Florida and New York, I have cultivated a rich clinical and academic career spanning over two decades.

At the University of Miami Hospital and Sylvester Comprehensive Cancer Center, I currently serve as an Assistant Professor of Clinical Medicine, specializing in pain and palliative medicine. In addition to providing comprehensive pain and symptom management to oncological patients, I lead the Opioid Stewardship Program developing policies and quality improvement projects to improve opioid prescribing practices.

My clinical expertise extends beyond academia, as demonstrated by my tenure as the Medical Director at South Florida Pain Relief Center and Miami Interventional Spine Specialists. In these roles, I specialized in managing chronic pain conditions, leveraging advanced interventional techniques and interdisciplinary collaboration to optimize patient outcomes. Beyond clinical practice, I am deeply engaged in research and education, with a robust portfolio of publications, presentations, and funded research projects. I am committed to advancing evidence-based practices in healthcare delivery.

I actively contribute to various university committees and professional organizations, including serving as Chair of the Opioid Stewardship Committee, Palliative medicine taskforce, ethics committee, pharmacy and therapeutics committee among others. As I continue to advance in my career, I remain dedicated to improving patient care, mentoring future healthcare leaders, and driving innovation in pain management and palliative care.

Yan Guo, Ph.D.

Dr. Guo's research in bioinformatics centers on the development and application of cutting-edge computational tools and algorithms to tackle key challenges in genomics and personalized medicine. With a focus on integrating diverse omics data, including genomics, transcriptomics, proteomics, and epigenomics, Dr. Guo aims to elucidate complex regulatory networks and molecular interactions underlying various biological processes and disease phenotypes.

By harnessing machine learning techniques and network analysis, Dr. Guo endeavors to identify novel biomarkers, therapeutic targets, and potential drug candidates, contributing to advancements in precision medicine and facilitating the translation of bioinformatics findings into clinical applications. Through this work, Dr. Guo seeks to make significant contributions to the understanding of biological systems and improve healthcare outcomes for individuals.

Karla Ballman, Ph.D.

Mayo Clinic: The research of Karla V. Ballman, Ph.D., focuses on the design and implementation of clinical trials, particularly for small patient populations and early detection and interception of disease. Also, Dr. Ballman works on biomarker development from high-dimensional data and the subsequent validation of these biomarkers.

Focus area: Early-phase clinical trials in cancer. Dr. Ballman develops clinical trial designs for small patient populations, such as rare cancers, to determine whether a new cancer treatment has sufficient activity to justify a larger clinical trial. Her focus is on using randomization in these trials, as well as the role of bootstrapping, to increase the ability to distinguish between promising and futile treatments. Breast cancer, genitourinary cancer and brain cancer. Dr. Ballman investigates the effects of new treatment options in large, multicenter, phase 3 clinical trials. The focus of these trials is to improve patients' long-term outcomes, such as reducing the risk of cancer recurrence or cancer progression or improving patient survival. She also evaluates whether treatments can be de-escalated in patients who have good outcomes to minimize overtreatment and personalize treatment. Biomarker development. Dr. Ballman collaborates with others to develop biomarkers using high-dimensional molecular data. Her particular interest is developing biomarkers that predict treatment benefit for particular treatment-disease combinations and biomarkers that are prognostic of disease outcomes.

Dr. Ballman's research has set new standards of treatment in breast cancer, bladder cancer, gastrointestinal stromal tumors and metastatic brain cancer. Her work adds to the development of biomarkers that can determine whether a patient is at a higher risk of prostate cancer coming back after initial removal of the cancer. Overall, Dr. Ballman's clinical trials provide evidence for the approval of new treatments that make patient outcomes better. Her work in biomarker development and validation yields crucial information for matching patients with the right treatments.

Mathew Oberley, M.D., Ph.D.

An expert in clinical diagnostics, Dr. Matthew J. Oberley joined Caris Life Sciences in 2019 and has held a series of leadership positions in laboratory management and technology deployment. As Senior Vice President, Chief Clinical Officer and Pathologist-in-Chief, he is responsible for clinical development strategy, patient safety, external stakeholder engagement and the management of laboratory-based clinical teams.

Dr. Oberley leads Caris' growing Pathologist and Molecular Genetics group, which includes over 40 board-certified and sub-specialty trained pathologists and molecular geneticists. He recently oversaw the development, clinical validation and deployment of a high-capacity digital pathology system at Caris. This system generates over a petabyte of data from more than 1M slide scans per year and has significantly improved laboratory efficiency.
Dr. Oberley has coauthored over 150 journal articles, book chapters and abstracts in the areas of molecular biology and genetics, diagnostics and hematologic malignancies.

Prior to joining Caris, Dr. Oberley was on the faculty at the University of Southern California and served as Director of Hematopathology at Children's Hospital Los Angeles. Dr. Oberley received his MD and PhD from the University of Wisconsin – Madison School of Medicine and Public Health and is board-certified in Anatomic, Clinical and Hematopathology.

Doug Fridsma, M.D., Ph.D.

An internationally recognized leader in health informatics, standards, interoperability and health IT strategy that has worked in academics, government, non-profit, healthcare and innovation companies. A unique, international perspective on healthcare informatics and health IT seeking to continue to change health and health care through informatics and health IT.

Praduman Jain

PJ has 18 years of broad global thought leadership in high tech, healthcare, wellness, media, telecom, mobile, broadband, internet, software, convergence and globalization and specializes in global technology, business and management. His ability to solve large, complex business problems has led to his successful tenure as a leader in strategy, revenue generation, operations and product management.

Alexander Everest, M.D.

Dr. Alexander Everest, founder of Elite American Health Systems, brings over 20 years of experience to key healthcare industry positions. He began his career as a student at the VA Medical Center, learning healthcare administration from his late father, Dr. Edwin Everest. After four years at the VA, he joined his father’s firm, West Coast Healthcare Consultants.

Madhu Behera, Ph.D

Madhusmita Behera, PhD, serves as chief informatics officer and as associate director of data sciences and informatics at Winship Cancer Institute of Emory University. In these roles, Dr. Behera drives digital transformation and research growth through innovation and the implementation of technology that can positively affect patient care, outcomes, and safety. She also serves as Emory University's chief research informatics officer, where she provides strategic direction and leads the prioritization of research-related informatics, data analytics, data science and AI initiatives across Emory University and Emory Healthcare, driving research growth and transformation through state-of-the-art technology and data solutions.

Dr. Behera conducts original research, with a significant publication record focused on cancer outcomes and population-based studies using real world data and evidence-based research.